See more : BANDAI NAMCO Holdings Inc. (7832.T) Income Statement Analysis – Financial Results
Complete financial analysis of Lantheus Holdings, Inc. (LNTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Lantheus Holdings, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ENC Digital Technology Co., Ltd (603869.SS) Income Statement Analysis – Financial Results
- ROHM Co., Ltd. (ROHCY) Income Statement Analysis – Financial Results
- Century Legend (Holdings) Limited (0079.HK) Income Statement Analysis – Financial Results
- Svenska Handelsbanken AB (publ) (SHB-B.ST) Income Statement Analysis – Financial Results
- Black Sesame Intl Hldg Ltd (2533.HK) Income Statement Analysis – Financial Results
Lantheus Holdings, Inc. (LNTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.lantheus.com
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.30B | 935.06M | 425.21M | 339.41M | 347.34M | 343.37M | 331.38M | 301.85M | 293.46M | 301.60M | 283.67M | 288.11M | 356.29M |
| Cost of Revenue | 586.89M | 353.36M | 237.51M | 200.65M | 172.53M | 168.49M | 169.24M | 164.07M | 157.94M | 176.08M | 206.31M | 212.91M | 261.08M |
| Gross Profit | 709.54M | 581.70M | 187.70M | 138.76M | 174.81M | 174.89M | 162.14M | 137.78M | 135.52M | 125.52M | 77.36M | 75.20M | 95.22M |
| Gross Profit Ratio | 54.73% | 62.21% | 44.14% | 40.88% | 50.33% | 50.93% | 48.93% | 45.64% | 46.18% | 41.62% | 27.27% | 26.10% | 26.72% |
| Research & Development | 77.71M | 311.68M | 44.97M | 32.79M | 20.02M | 17.07M | 18.13M | 12.20M | 14.36M | 13.67M | 30.46M | 40.60M | 40.95M |
| General & Administrative | 125.46M | 133.58M | 150.40M | 69.27M | 61.24M | 50.17M | 49.84M | 38.83M | 43.89M | 37.31M | 33.04M | 32.52M | 32.86M |
| Selling & Marketing | 141.74M | 100.24M | 68.42M | 40.90M | 41.89M | 43.16M | 42.32M | 36.54M | 34.74M | 35.12M | 35.23M | 37.44M | 38.69M |
| SG&A | 267.19M | 233.83M | 218.82M | 110.17M | 103.13M | 93.33M | 92.16M | 75.37M | 78.63M | 72.43M | 68.26M | 69.96M | 71.55M |
| Other Expenses | 0.00 | -1.70M | -7.35M | 2.20M | -6.22M | 2.47M | 8.64M | 220.00K | -89.00K | 3.00K | 9.25M | 34.80M | 205.00K |
| Operating Expenses | 344.90M | 545.51M | 263.78M | 142.96M | 123.15M | 110.40M | 110.28M | 87.58M | 92.99M | 86.10M | 98.72M | 110.56M | 112.50M |
| Cost & Expenses | 931.79M | 898.87M | 501.30M | 343.61M | 295.68M | 278.89M | 279.53M | 251.65M | 250.93M | 262.18M | 305.03M | 323.47M | 373.57M |
| Interest Income | 19.64M | 2.61M | 45.00K | 238.00K | 686.00K | 167.00K | 18.00K | 0.00 | 24.00K | 27.00K | 104.00K | 252.00K | 333.00K |
| Interest Expense | 20.02M | 7.19M | 7.75M | 9.48M | 13.62M | 17.41M | 18.41M | 26.62M | 38.72M | 42.29M | 42.92M | 42.01M | 37.66M |
| Depreciation & Amortization | 60.04M | 47.93M | 42.29M | 24.69M | 13.38M | 13.86M | 19.14M | 18.26M | 19.65M | 18.25M | 25.16M | 27.40M | 32.76M |
| EBITDA | 491.01M | 81.83M | -25.00M | 22.69M | 55.62M | 80.81M | 77.19M | 73.18M | 46.59M | 58.17M | 7.53M | 26.86M | 17.74M |
| EBITDA Ratio | 37.87% | 3.69% | -19.62% | -0.59% | 13.08% | 19.50% | 18.25% | 16.70% | 14.47% | 19.13% | 4.63% | 9.40% | 4.50% |
| Operating Income | 364.64M | -13.44M | -76.09M | -4.20M | 32.06M | 64.49M | 51.85M | 56.59M | 42.53M | 39.42M | -18.89M | -750.00K | -17.28M |
| Operating Income Ratio | 28.13% | -1.44% | -17.89% | -1.24% | 9.23% | 18.78% | 15.65% | 18.75% | 14.49% | 13.07% | -6.66% | -0.26% | -4.85% |
| Total Other Income/Expenses | 46.30M | -9.48M | -14.21M | -7.28M | -23.03M | -14.94M | -12.21M | -28.29M | -54.31M | -41.78M | -41.65M | -7.19M | -35.90M |
| Income Before Tax | 410.94M | 26.72M | -75.04M | -11.48M | 28.63M | 49.55M | 39.64M | 28.29M | -11.78M | -2.37M | -60.54M | -42.56M | -53.18M |
| Income Before Tax Ratio | 31.70% | 2.86% | -17.65% | -3.38% | 8.24% | 14.43% | 11.96% | 9.37% | -4.01% | -0.78% | -21.34% | -14.77% | -14.92% |
| Income Tax Expense | 84.28M | -1.35M | -3.76M | 1.99M | -3.04M | 9.03M | -83.75M | 1.53M | 2.97M | 1.20M | 1.01M | -555.00K | 84.08M |
| Net Income | 326.66M | 28.07M | -71.28M | -13.47M | 31.67M | 40.52M | 123.39M | 26.76M | -14.75M | -3.56M | -61.56M | -42.00M | -137.26M |
| Net Income Ratio | 25.20% | 3.00% | -16.76% | -3.97% | 9.12% | 11.80% | 37.23% | 8.87% | -5.02% | -1.18% | -21.70% | -14.58% | -38.52% |
| EPS | 4.79 | 0.41 | -1.06 | -0.25 | 0.81 | 1.06 | 3.31 | 0.84 | -0.60 | -0.20 | -3.40 | -2.36 | -7.61 |
| EPS Diluted | 4.65 | 0.40 | -1.06 | -0.25 | 0.79 | 1.03 | 3.17 | 0.82 | -0.60 | -0.20 | -3.34 | -2.32 | -7.61 |
| Weighted Avg Shares Out | 68.27M | 68.49M | 67.49M | 54.13M | 38.99M | 38.23M | 37.28M | 32.04M | 24.44M | 17.81M | 18.08M | 17.79M | 18.03M |
| Weighted Avg Shares Out (Dil) | 70.24M | 70.67M | 67.49M | 54.13M | 40.11M | 39.50M | 38.89M | 32.66M | 24.44M | 18.08M | 18.40M | 18.08M | 18.03M |
Buy These 3 Beaten-Down MedTech Stocks for a Turnaround Soon
Lantheus' AI-Enabled aPROMISE Now Available on Siemens Healthineers' syngo.via platform
Lantheus Holdings (LNTH) Upgraded to Strong Buy: What Does It Mean for the Stock?
Best Momentum Stocks to Buy for May 31st
Here's Why You Should Add Lantheus (LNTH) to Your Portfolio Now
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
Are Medical Stocks Lagging Lantheus (LNTH) This Year?
Lantheus to Present at the William Blair 44th Annual Growth Stock Conference
Is Lantheus Holdings (LNTH) a Solid Growth Stock? 3 Reasons to Think "Yes"
Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 31.21%: Here's is How to Trade
Source: https://incomestatements.info
Category: Stock Reports